HighTower Advisors LLC Buys 5,377 Shares of Insulet Corporation $PODD

HighTower Advisors LLC increased its stake in Insulet Corporation (NASDAQ:PODD) by 211.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,921 shares of the medical instruments supplier’s stock after acquiring an additional 5,377 shares during the quarter. HighTower Advisors LLC’s holdings in Insulet were worth $2,251,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after acquiring an additional 87,845 shares in the last quarter. Northern Trust Corp increased its stake in shares of Insulet by 0.5% in the 3rd quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after acquiring an additional 3,618 shares in the last quarter. Qube Research & Technologies Ltd increased its stake in shares of Insulet by 37.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after acquiring an additional 156,009 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after acquiring an additional 142,922 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its stake in shares of Insulet by 0.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 494,712 shares of the medical instruments supplier’s stock valued at $152,703,000 after acquiring an additional 4,057 shares in the last quarter.

Insulet Stock Performance

Shares of PODD stock opened at $144.94 on Monday. The firm has a market capitalization of $10.04 billion, a PE ratio of 33.71, a price-to-earnings-growth ratio of 1.14 and a beta of 1.13. The firm has a fifty day simple moving average of $183.55 and a two-hundred day simple moving average of $244.77. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 12 month low of $140.63 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. Insulet’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts forecast that Insulet Corporation will post 6.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the subject of several research analyst reports. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Bank of America lowered their price objective on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. William Blair began coverage on shares of Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating for the company. Truist Financial decreased their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Finally, BTIG Research decreased their price target on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a research note on Tuesday, May 26th. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $252.04.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.